CN116970501B - Triplex solid fermentation preparation and preparation method and application thereof - Google Patents
Triplex solid fermentation preparation and preparation method and application thereof Download PDFInfo
- Publication number
- CN116970501B CN116970501B CN202310944965.5A CN202310944965A CN116970501B CN 116970501 B CN116970501 B CN 116970501B CN 202310944965 A CN202310944965 A CN 202310944965A CN 116970501 B CN116970501 B CN 116970501B
- Authority
- CN
- China
- Prior art keywords
- preparation
- triple
- solid state
- fermentation
- state fermentation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000855 fermentation Methods 0.000 title claims abstract description 109
- 230000004151 fermentation Effects 0.000 title claims abstract description 109
- 238000002360 preparation method Methods 0.000 title claims abstract description 108
- 239000007787 solid Substances 0.000 title claims abstract description 77
- 241000233866 Fungi Species 0.000 claims abstract description 35
- 238000010563 solid-state fermentation Methods 0.000 claims abstract description 33
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 claims abstract description 24
- 244000253911 Saccharomyces fragilis Species 0.000 claims abstract description 24
- 235000018368 Saccharomyces fragilis Nutrition 0.000 claims abstract description 24
- 229940031154 kluyveromyces marxianus Drugs 0.000 claims abstract description 24
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 23
- 235000014469 Bacillus subtilis Nutrition 0.000 claims abstract description 23
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 21
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 21
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 21
- 244000005700 microbiome Species 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 230000029087 digestion Effects 0.000 claims abstract description 10
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 230000014759 maintenance of location Effects 0.000 claims abstract description 4
- 241000894006 Bacteria Species 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 20
- 238000004321 preservation Methods 0.000 claims description 19
- 206010009887 colitis Diseases 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 235000015099 wheat brans Nutrition 0.000 claims description 12
- 238000009629 microbiological culture Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 230000001737 promoting effect Effects 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 235000013312 flour Nutrition 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 238000011081 inoculation Methods 0.000 claims description 5
- 235000001405 Artemisia annua Nutrition 0.000 claims description 4
- 240000000011 Artemisia annua Species 0.000 claims description 4
- 244000018633 Prunus armeniaca Species 0.000 claims description 4
- 235000009827 Prunus armeniaca Nutrition 0.000 claims description 4
- 240000001417 Vigna umbellata Species 0.000 claims description 4
- 235000011453 Vigna umbellata Nutrition 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 240000000275 Persicaria hydropiper Species 0.000 claims description 2
- 235000017337 Persicaria hydropiper Nutrition 0.000 claims description 2
- 241001251949 Xanthium sibiricum Species 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 31
- 241000699670 Mus sp. Species 0.000 description 64
- 238000002474 experimental method Methods 0.000 description 20
- 210000001072 colon Anatomy 0.000 description 19
- 229920003045 dextran sodium sulfate Polymers 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 13
- 230000001976 improved effect Effects 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 102000004889 Interleukin-6 Human genes 0.000 description 9
- 108090001005 Interleukin-6 Proteins 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 235000008085 high protein diet Nutrition 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 102000003814 Interleukin-10 Human genes 0.000 description 7
- 108090000174 Interleukin-10 Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 235000000346 sugar Nutrition 0.000 description 7
- 102400000921 Gastrin Human genes 0.000 description 6
- 108010052343 Gastrins Proteins 0.000 description 6
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 208000004232 Enteritis Diseases 0.000 description 5
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 208000035861 hematochezia Diseases 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000000112 colonic effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 238000003794 Gram staining Methods 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000003629 gastrointestinal hormone Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000002175 goblet cell Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000194103 Bacillus pumilus Species 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 101001002314 Mus musculus Gastrin Proteins 0.000 description 2
- 244000292697 Polygonum aviculare Species 0.000 description 2
- 235000006386 Polygonum aviculare Nutrition 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241001506766 Xanthium Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940017800 lactobacillus casei Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 235000021110 pickles Nutrition 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108091023242 Internal transcribed spacer Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000433 anti-nutritional effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000008951 colonic inflammation Effects 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000010271 massa medicata fermentata Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 235000020255 yak milk Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
- A23K10/37—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms from waste material
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- C12N1/165—Yeast isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
- C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Sustainable Development (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a triple fungus solid fermentation preparation, a preparation method and application thereof, and relates to the technical field of biology. The preparation method comprises the step of carrying out solid state fermentation on the raw materials for preparing the medicated leaven by utilizing a microorganism combination to prepare the triple fungus solid state fermentation preparation. The microorganism combination comprises Kluyveromyces marxianus (Kluyveromyces marxianus) JSA16, lactobacillus plantarum (Lactiplantibacillus plantarum) BY3 and Bacillus subtilis (Bacillus subtilis) BK3. The invention firstly uses Kluyveromyces marxianus, lactobacillus plantarum and bacillus subtilis to carry out mixed solid state fermentation, and develops a triple fungus solid state fermentation preparation which can relieve food retention and promote digestion and has the effect of relieving colonitis.
Description
Technical Field
The invention relates to the technical field of biology, in particular to a triple fungus solid fermentation preparation and a preparation method and application thereof.
Background
Probiotics are living microorganisms that are capable of providing health benefits to a host when administered in amounts and contain an active amount during the useful life and are safe for their intended use. Many studies have shown that probiotics can enhance human health in a variety of ways, which can improve intestinal microbial composition, regulate human immune function, and prevent or reduce the occurrence of a variety of diseases.
Solid state fermentation is one of fermentation processes, mainly refers to one or more microbial fermentation processes in an environment without any free water, or with water of a certain humidity but not dissolved in a solid substrate, and the whole process is mainly biological reaction; in a broader definition, solid state fermentation can be regarded as a process comprising culturing microorganisms in the presence of a liquid phase of a maximum substrate concentration or inert carrier. Compared with other fermentation processes, the solid fermentation medium has wide and easily obtained raw materials, and most of the raw materials are residues in the agricultural food industry; the wastewater yield is low, the use of chemical substances such as defoamer and the like can be avoided, and the environmental protection advantage is realized; the cost of the culture medium is low, the water consumption is low, the conversion rate of the product is high, and the method has good economic benefit.
The solid state fermentation can simultaneously convert macromolecules and anti-nutritional factors which are difficult to utilize in agricultural residues such as bran, plant meal cake and the like into nutritional feed which can be absorbed and utilized. The nutrition characteristic, digestibility, palatability and safety of the feed can be improved after fermentation treatment.
Massa Medicata Fermentata was originally recorded in Ben Cao gang mu, and is also discussed in Yao xing Lun. The solid fermentation preparation is a starter prepared by mixing wheat bran, flour, bitter apricot kernel, red bean, fresh sweet wormwood, fresh polygonum hydropiper and fresh xanthium in a certain proportion and then fermenting by microorganisms, and is mainly used for treating weakness of spleen and stomach, chest and abdominal distention, food stagnation, infantile indigestion and the like.
The traditional fermentation strains of the medicated leaven are mostly mould such as mucor, aspergillus, and the like, the traditional fermentation process is long in time, the quantity and the types of microorganisms are not easy to control, the difference among product batches is large, and other microorganisms in natural fermentation can generate harmful metabolites such as aflatoxin, and the like, which are easy to cause black and peculiar smell of the yeast, toxin, and the like; traditional medicated leaven is mostly used for aiding digestion and has single purpose. Therefore, it is necessary to develop a process of combined fermentation by adopting pure-bred and safe multiple strains, so as to enhance the application scene of the fermented materials of the medicated leaven, and achieve the effects of good sensory quality and high application value of the solid state fermentation preparation of the medicated leaven.
Disclosure of Invention
The invention aims to provide a triple fungus solid fermentation preparation, a preparation method and application thereof, and aims to solve the problems in the prior art.
In order to achieve the above object, the present invention provides the following solutions:
The invention provides a microorganism combination for improving fermentation quality of medicated leaven, which comprises Kluyveromyces marxianus (Kluyveromyces marxianus) JSA16, lactobacillus plantarum (Lactiplantibacillus plantarum) BY3 and bacillus subtilis (Bacillus subtilis) BK3;
the Kluyveromyces marxianus JSA16 is preserved in the China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) for 2023, wherein the preservation address is number 3 of West Song No.1 of the Korean area North Star of Beijing, and the preservation number is CGMCC No.26422;
The lactobacillus plantarum BY3 is preserved in the China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) at the 12 th month of 2022, and has a preservation address of the No. 1 or 3 of the West-Lou No. 1 of the Korean area North Star of Beijing, and a preservation number of the CGMCC No.26262;
The bacillus subtilis BK3 is preserved in China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) at the 12 th month of 2022, and has a preservation address of number 3 of West Song No. 1 of the Korean region North Star of Beijing, and a preservation number of CGMCC No. 26160.
The invention also provides application of the microorganism combination in preparation of a triple fungus solid fermentation preparation.
The invention also provides a preparation method of the triple fungus solid fermentation preparation, which comprises the step of preparing the triple fungus solid fermentation preparation by using the microorganism combination to perform solid fermentation on the raw materials for preparing the medicated leaven.
Further, the medicated leaven comprises 50 parts of wheat bran, 25 parts of flour, 1 part of bitter apricot seed, 1 part of red bean, 5 parts of flaccid knotweed herb, 5 parts of sweet wormwood herb and 5 parts of cocklebur fruit according to parts by weight.
Further, the preparation method comprises the following steps:
(1) Pulverizing testa Tritici, flour and semen Armeniacae amarum, sterilizing and drying, adding water decoction of herba Polygoni Capitati, herba Artemisiae Annuae and herba Xanthii, and mixing to obtain solid fermentation preparation material;
(2) Inoculating the kluyveromyces marxianus JSA16, the lactobacillus plantarum BY3 and the bacillus subtilis BK3 into the solid fermentation preparation raw materials to prepare a yeast block, and performing solid fermentation to obtain the triple bacteria solid fermentation preparation.
Further, in the step (2), the inoculation mass fractions of the kluyveromyces marxianus JSA16, the lactobacillus plantarum BY3 and the bacillus subtilis BK3 with respect to the solid state fermentation preparation raw material are 3%, 3% and 12%, respectively.
Further, in the step (2), the temperature of the solid state fermentation is 30 ℃ and the time is 4d.
The invention also provides a triple bacteria solid fermentation preparation prepared by the preparation method.
The invention also provides application of the triple fungus solid fermentation preparation in preparing feed, health care product or medicine for relieving food retention and/or promoting digestion.
The invention also provides application of the triple fungus solid fermentation preparation in preparing feed, health care products or medicines for preventing colonitis.
The invention discloses the following technical effects:
1. The invention firstly uses Kluyveromyces marxianus, lactobacillus plantarum and bacillus subtilis to carry out mixed solid fermentation, and develops a triple-fungus solid fermentation preparation which can relieve food stagnation caused by high-protein diet, play a certain role in promoting digestion, and also can increase secretion of gastrointestinal hormone and maintain balance of intestinal tract environment; the solid fermentation preparation of the triple bacteria also has the function of preventing colonitis; in addition, the triple fungus solid fermentation preparation has soft smell and sour flavor; golden yellow, good quality and wide market application scene.
2. The three strains used in the invention are all good functional strains, the Kluyveromyces marxianus JSA16 is derived from traditional fermented yak milk, the growth is rapid, the protease activity is realized, the fermented wheat bran product has fruit fragrance, and the polypeptide content is improved; the lactobacillus plantarum BY3 is derived from traditional pickle of northeast farmhouse, has the advantages of high growth speed, low temperature resistance and the like, and can inhibit the growth of pathogenic bacteria BY a large amount of organic acid generated in the fermentation process; the bacillus subtilis BK3 is derived from traditional pickle of northeast farmhouse, has rapid growth, strong stress resistance and a large amount of enzymes in metabolites, and has higher protease activity and cellulase activity required by wheat bran decomposition.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are needed in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and other drawings may be obtained according to these drawings without inventive effort for a person skilled in the art.
FIG. 1 is a diameter of a lactobacillus zone of inhibition;
FIG. 2 shows the protease activity of Bacillus;
FIG. 3 is a graph of yeast growth curve;
FIG. 4 is a graph showing diameter of a circle of enzymatic hydrolysis of yeast;
FIG. 5 is a colony morphology and strain morphology map;
FIG. 6 is a biological evolutionary tree of JSA 16;
FIG. 7 is a biological phylogenetic tree of BY 3;
FIG. 8 is a biological evolutionary tree of BK 3;
FIG. 9 shows the content of the fermented soluble polypeptide in different combinations;
FIG. 10 is a graph showing the content of different combinations of fermentation reducing sugars;
FIG. 11 shows the amounts of fermented soluble polypeptide content with different inoculum sizes;
FIG. 12 is a graph of the fermentation reducing sugar content at different inoculum sizes;
FIG. 13 shows the L-glutamine content of the fermented seed amount;
FIG. 14 is a flow chart of the preparation method of example 4;
FIG. 15 is a diagram of the final solid fermentation preparation of the triple bacteria of example 4;
FIG. 16 is a schematic diagram of the experimental group of food retention model animals in example 5;
FIG. 17 is a graph showing the effect of a solid fermentation preparation of triple bacteria on stool parameters of mice in animal experiments;
FIG. 18 is a graph showing the effect of a triple solid fermentation preparation on the rate of intestinal thrust in mice;
FIG. 19 is a graph showing the results of the effect of a triple fungus solid state fermentation formulation on mouse gastrin;
Fig. 20 is a schematic diagram of experimental groups of animals in the colitis model of example 6;
FIG. 21 is a graph showing the effect of a solid fermentation preparation of triple bacteria on mouse hematochezia;
FIG. 22 is a graph showing the effect of a triple fungus solid state fermentation formulation on colon length in mice;
FIG. 23 is a graph showing the effect of the solid fermentation preparation of triple bacteria on IL-6, TNF-alpha and IL-10 in mice;
FIG. 24 is a slice diagram of the effect of a triple fungus solid state fermentation formulation on the colon morphology of mice.
Detailed Description
Various exemplary embodiments of the invention will now be described in detail, which should not be considered as limiting the invention, but rather as more detailed descriptions of certain aspects, features and embodiments of the invention.
It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. In addition, for numerical ranges in this disclosure, it is understood that each intermediate value between the upper and lower limits of the ranges is also specifically disclosed. Every smaller range between any stated value or stated range, and any other stated value or intermediate value within the stated range, is also encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included or excluded in the range.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although only preferred methods and materials are described herein, any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. All documents mentioned in this specification are incorporated by reference for the purpose of disclosing and describing the methods and/or materials associated with the documents. In case of conflict with any incorporated document, the present specification will control.
It will be apparent to those skilled in the art that various modifications and variations can be made in the specific embodiments of the invention described herein without departing from the scope or spirit of the invention. Other embodiments will be apparent to those skilled in the art from consideration of the specification of the present invention. The specification and examples of the present invention are exemplary only.
As used herein, the terms "comprising," "including," "having," "containing," and the like are intended to be inclusive and mean an inclusion, but not limited to.
EXAMPLE 1 preliminary screening of strains
The invention adopts oxford cup method, uses wheat bran as fermentation substrate, uses escherichia coli (3.97X10 8 CFU/mL) and staphylococcus aureus (3.53X10 8 CFU/mL) as indicator bacteria, and determines the content of escherichia coli according to GB4789.3-2016 method; GB4789.10-2016 shows the measurement of Staphylococcus aureus content, as shown in FIG. 1. Wherein the bacteriostasis circle of the lactobacillus plantarum BY3, the lactobacillus plantarum S6 and the lactobacillus casei LH23 is superior to other strains.
Bacillus with protease activity was selected by Fu Lin Fen method, and the result is shown in FIG. 2. Wherein the content of the soluble polypeptide of the bacillus pumilus Y2 and the bacillus subtilis BK3 after fermentation is superior to that of other strains.
Yeast with good growth curve is screened by adopting the measurement of the growth curve and the protease transparent circle experiment, and the results are shown in FIG. 3 and FIG. 4. Wherein the growth curve of Kluyveromyces marxianus JSA16 and Saccharomyces cerevisiae J2 is superior to other strains.
The wheat bran is used as a fermentation substrate, single-strain fermentation is carried out, sensory evaluation is carried out on the fermented wheat bran, the sensory evaluation criteria are shown in table 1 and table 2, wherein the feed after BY3 fermentation has apple vinegar fragrance, the feed after JSA16 fermentation has wine fragrance, the feed after LH23 fermentation has bean fragrance and slight cheese fragrance, and the fermentation feeds of BY3 and J2 are free of caking.
TABLE 1
TABLE 2
And synthesizing the results of single-strain fermentation, wherein the finally determined fermentation strains are bacillus subtilis BK3, bacillus pumilus Y2, lactobacillus plantarum BY3, lactobacillus plantarum S6, lactobacillus casei LH23, kluyveromyces marxianus JSA16 and kluyveromyces marxianus J2.
The identification process of the JSA16, BY3 and BK3 is as follows:
The JSA16 colony is round, large and thick, and has neat edges and milky white (see figure 5); gram staining to G +, extracting strain genome from the thallus ellipse by using a fungus genome DNA rapid extraction kit, and carrying out PCR amplification by using ITS1 and ITS4 as primers by using the genome as a template. The amplified PCR products were sequenced and spliced to DNA sequences, and sequence homology was analyzed using the BLAST search system at NCBI (fig. 6). JSA16 was finally identified as Kluyveromyces marxianus (Kluyveromyces marxianus).
BY3 colonies are smaller, round, white, opaque, protruding, moist and flat in edge (see FIG. 5); gram staining to G +, extracting bacterial genome with bacterial genome DNA fast extraction kit, and PCR amplification with 27F and 1492R as primer. The amplified PCR products were sequenced and spliced to DNA sequences, and sequence homology was analyzed using the BLAST search system at NCBI (fig. 7). BY3 was finally identified as Lactobacillus plantarum (Lactiplantibacillus plantarum).
BK3 colonies were large, or white, rough, irregular in edge, and the colony surfaces had protrusions and wrinkles (see FIG. 5); gram staining to obtain G +, extracting bacterial genome with bacterial genome DNA fast extraction kit, and PCR amplification with 27F and 1492R as primer. The amplified PCR products were sequenced and spliced to DNA sequences, and sequence homology was analyzed using the BLAST search system at NCBI (fig. 9). BK3 was finally identified as Bacillus subtilis (Bacillus subtilis).
Strain preservation:
Kluyveromyces marxianus JSA16 is preserved in China general microbiological culture Collection center (CGMCC) for 2023, wherein the preservation address is number 3 of West Song No. 1 of the Korean area North Star of Beijing city, and the preservation number is CGMCC No.26422; the lactobacillus plantarum BY3 is preserved in China general microbiological culture collection center (CGMCC) at the 12 th month of 2022 with the preservation address of the China general microbiological culture Collection center (CGMCC) of the North Star Xiyu No. 1, no. 3 of the Korean area of Beijing city and the preservation number of the CGMCC No.26262; the bacillus subtilis BK3 is preserved in China general microbiological culture Collection center (CGMCC) at the 12 th month of 2022 with the preservation address of North Star Xili No. 1,3 in the Korean region North Star in Beijing city and the preservation number of CGMCC No.26260.
Example 2 determination of Mixed fermentation combinations
Wheat bran is used as a fermentation substrate, and the proportion of mixed fermentation inoculation is as follows: lactic acid bacteria: bacillus=3% (w/w): 3% (w/w): 3% (w/w), fermenting at 30deg.C for 6d, and fermenting three bacteria in parallel. The content of soluble polypeptide is shown in figure 7, compared with an unfermented feed group, the content of soluble polypeptide of the combination jsa16+by3+bk3, jsa16+by3+y2 and j2+by3+bk3 is improved, wherein the content of soluble polypeptide of the combination jsa16+by3+bk3 after fermentation is the highest, the difference is obvious (P < 0.05), the content of soluble polypeptide of the feed after fermentation of the combination jsa16+s6+y2 is obviously improved, and the difference is extremely obvious (P < 0.01); the reducing sugar content is shown in fig. 10, the reducing sugar content of the combinations jsa16+by3+bk3, j2+by3+bk3 and j2+by3+y2 is increased compared to the unfermented feed group, and the difference is very significant (P < 0.01). The reducing sugar and the soluble polypeptide are used as detection indexes to determine the mixed bacteria fermentation combination into four groups of JSA16+BY3+BK3, JSA16+BY3+Y2, J2+BY3+BK3 and J2+BY3+Y2.
Example 3 determination of optimal Mixed fermentation combinations and inoculum size
The seven groups of combinations are fermented in different inoculation proportions by taking the content of soluble polypeptide (figure 11) and the content of reducing sugar (figure 12) of the fermented feed and the content of L-glutamine (figure 13) as detection indexes and wheat bran as fermentation substrates. Mixed bacteria fermentation inoculation proportion yeast (w/w): lactic acid bacteria (w/w): bacillus (w/w) was 3%:3%:3% and 3%:3%:12%, fermenting at 30deg.C for 6d, and fermenting three bacteria in parallel.
The final mixed bacteria fermentation combination is determined to be 3% (w/w) of Kluyveromyces marxianus JSA16, 3% (w/w) of lactobacillus plantarum BY3 and 12% (w/w) of bacillus subtilis BK3, and the final mixed bacteria fermentation combination is specifically characterized in that the total acid content of the fermented wheat bran is 1.16g/100g, the acidity pH value is 4.17, the total acid yield is obviously improved, the mixed bacteria can be inhibited, the content of soluble polypeptide is improved to 3.15 times, the content of reducing sugar is improved to 2.84 times, and the content of L-glutamine is improved to 1.64 times.
EXAMPLE 4 preparation of solid fermentation preparation
As shown in fig. 14, the preparation method of the triple fungus solid state fermentation preparation comprises the following steps:
(1) Preparing triple bacteria: activating Kluyveromyces marxianus JSA16, lactobacillus plantarum BY3 and bacillus subtilis BK3 for three times, culturing for 7 hours until the bacterial body amount is not less than 10 7 CFU/mL, and centrifuging at 4 ℃ and 4000r/min for 15 minutes to collect bacterial bodies.
(2) Preparing raw materials of a solid fermentation preparation: 50 parts of wheat bran, 25 parts of flour, 1 part of bitter apricot kernel and 1 part of red bean, crushing the mixture by a high-speed crusher, sterilizing the crushed mixture for 15min, and drying the crushed mixture at 45 ℃;5 parts of flaccid knotweed herb, 5 parts of sweet wormwood herb, 5 parts of siberian cocklebur fruit, adding 10 times of purified water, decocting and leaching for 1h, and concentrating by a rotary evaporator for 5 times; mixing the above materials to obtain solid fermentation preparation.
(3) Inoculating: under a sterile environment, inoculating triple bacteria into the solid fermentation preparation raw material, wherein Kluyveromyces marxianus JSA16 is 3% (w/w), lactobacillus plantarum BY3 is 3% (w/w), bacillus subtilis BK3 is 12% (w/w), and inoculating the solid fermentation preparation raw material BY 20mL of sterile water in a heavy suspension manner.
(4) Fermentation: the total water content of the solid fermentation preparation is controlled to be 45%, the solid fermentation preparation is prepared into a curved block under the aseptic environment, twelve layers of gauze are covered and placed into a constant temperature incubator at 30 ℃, the humidity is controlled to be 80%, the solid fermentation preparation is fermented for 4 days until the solid fermentation preparation emits sour flavor, the content changes of each component before and after fermentation are shown in a table 3, and a finished product is shown in fig. 15.
(5) And (3) drying: and (3) drying the solid fermentation preparation after fermentation for 12 hours at the temperature of 75 ℃ in a forced air drying oven until the surface of the solid fermentation preparation is micro-burnt, so as to obtain the triple bacteria solid fermentation preparation.
(6) Decocting: adding 10 times of purified water into the solid fermentation preparation of the triple bacteria, boiling, filtering with four layers of gauze, and forming a solid fermentation preparation decoction with solid content of 0.1g/mL for later use.
TABLE 3 Table 3
Example 5 animal experiment group of digestion promoting effect of Triplex solid fermentation preparation on indigestible mice
As shown in fig. 16, animal experiment tests for digestion promotion of the triple fungus solid fermentation preparation prepared in example 5:
The experimental animals were 18 male Kunming mice, fed at room temperature, fed with free diet, and after 7 days of adaptive feeding, were randomly divided into 3 groups, namely, a normal group (NC), a high protein induced food accumulation model group (HPD) and a solid state fermentation preparation group (LSQ), 6 each. The NC group is fed with normal feed, and the HPD group and the LSQ group are both fed with high-protein feed; the NC group and the HPD group drink normal water, and the LSQ group drinks the solid fermentation preparation decoction prepared in example 5 for four weeks. The following tests were then performed:
1. determination of the Effect of solid fermentation preparations on the Small intestine Propulsion of mice
The effect of the triple fungus solid fermentation preparation on the small intestine propulsion of the mice is determined by adopting a gastric lavage semi-solid nutrition paste mode. Four weeks of animal experiments, after the experiments, the mice are fasted for 12 hours without water control, 0.4mL of semi-solid nutrition paste is filled into the stomach, after 20 minutes, the mice are killed by cervical dislocation, the parts from the stomach to the ileocecum of the mice are taken, the parts from the stomach to the ileocecum of the mice are straightened under the condition of no additional external force, the distance from the pylorus of the stomach to the front edge of the semi-solid nutrition paste and the total length of the small intestine from the pylorus to the ileocecum of the mice are measured, and the propulsion rate of the small intestine of the mice is calculated.
As shown in fig. 17-18, experimental data indicate that continuous four-week high protein diet, mice in the HPD group had a slower intestinal transit rate and mice in the LSQ group had an improved intestinal transit rate. Specifically, LSQ group mice showed a significant increase in intestinal transit rate and significant variability (P < 0.05) compared to HPD group mice. This shows that the triple fungus solid fermentation preparation has the effect of promoting the small intestine propulsion on high protein diet mice, thereby having the beneficial effect of promoting digestion.
2. Determination of the Effect of triple solid fermentation preparation on mouse gastrin
ELISA method is used to measure the effect of the solid fermentation preparation of the triple bacteria on the gastrin of the mice. Four weeks after the animal experiment, the mice were sacrificed after the end of the experiment, the whole stomach of the mice was taken, and the gastric residues were removed. 8 grinding beads and 900 mu LPBS were added to a 1.5mL EP tube, and 0.1g of stomach tissue was placed therein; fully homogenizing by using a homogenizer added with liquid nitrogen, and centrifuging for 10min by using a high-speed refrigerated centrifuge 8000 r/min; the supernatant was aspirated and gastrin was determined using a gastrin ELISA kit.
Gastrin is an excitatory gastrointestinal hormone, which is mainly secreted by G cells of the antrum and duodenum, and promotes pepsin secretion and gastrointestinal motility, thereby promoting gastrointestinal motility. As shown in fig. 19, experimental data indicate that the LSQ group mice have significantly elevated gastrin levels and significantly different (P < 0.01) levels compared to the HPD group mice on a continuous four week high protein diet. The triple fungus solid fermentation preparation has the effects of regulating the secretion of gastrointestinal hormone to promote gastrointestinal movement and improve gastric motility disorder on high-protein diet mice, thereby having the beneficial effect of promoting digestion.
In summary, the in vivo experiment in this example shows that the small intestine propulsion rate and gastrin content of the solid state fermentation preparation group are improved compared with the model group by the four-week high protein diet; and has significant differences; in addition, the feces of the mice in the model group are dark, and compared with the solid fermentation preparation group, the feces have lighter color, obviously improved water content and healthfulness. The solid fermentation preparation prepared by the method has a certain effect of relieving food stagnation caused by high-protein diet and has the effect of promoting digestion. For food stagnation caused by high protein diet digestive system diseases such as dyspepsia have important practical significance.
Example 6 animal experiment group of the protective action of Triplex solid fermentation preparation on mice with colitis
As shown in fig. 20, animal experiment groups and operations of the triple fungus solid state fermentation preparation for protecting colon effect:
The experimental animals were 18 male C57BL/6 mice, fed at room temperature, fed with free diet, and after 7 days of adaptive feeding, were randomly divided into 3 groups, namely, 6 groups of normal group (NC), dextran Sodium Sulfate (DSS) -induced colitis model group (DSS) and solid state fermentation preparation group (LSQ). Normal group and model group were perfused with 0.3mL physiological saline per day, solid state fermentation preparation group was perfused with 0.3mL concentrated solution (0.4 g/mL) of the triple fungus solid state fermentation preparation prepared in example 5 per day, feed and drinking water conditions were the same, and at week 3 of the experiment, mice of model group and solid state fermentation preparation group were replaced with 2.5% dss drinking water, and feeding was continued for 7 days. The following tests were then performed:
1. Observing the influence of the solid fermentation preparation of the triple bacteria on the hematochezia condition of mice with enteritis
Mice were observed daily for hematochezia after molding by feeding dextran sodium sulfate.
Symptoms of mouse colitis are mainly manifested as ulcerative bleeding of the colon, and blood adheres to feces or to outflow. As shown in fig. 21, five days after molding, mice in DSS group had hematochezia, and gradually aggravated, and LSQ group hematochezia was improved, which indicates that the triple bacteria solid fermentation preparation can form protection in intestinal tract, and alleviate colitis symptoms.
2. Determination of the Effect of the triple solid fermentation preparation on colon Length of mice with colon inflammation
After four weeks of animal experiments, the cervical dislocation method is used for completely shearing the cecum to the anus after the mice are killed, straightening the mice without additional external force, and measuring the length from the lower end of the cecum to the upper end of the anus, namely the colon length.
Colonic shortening is one of the main manifestations of the acute colitis model, and an increase in colonic length can prove an improvement in colonic inflammation in mice. As shown in fig. 22, experimental data indicate that LSQ group mice have significantly longer colon lengths than DSS group mice. This shows that the triple fungus solid state fermentation preparation has certain effect of relieving and protecting the mice with the enteritis.
3. Determination of the Effect of Triplex solid fermentation preparation on inflammatory factor IL-6 in mice with enteritis
ELISA method is used for measuring the influence of the triple fungus solid fermentation preparation on the mouse inflammatory factor IL-6. Four weeks of animal experiment, collecting blood from eyeballs of mice after the experiment is finished, solidifying the blood at room temperature for 30min, and centrifuging at 3000r/min for 15min; the supernatant was aspirated and the content was determined using an IL-6ELISA kit.
IL-6 is a cytokine capable of modulating and activating immune cells, thereby mediating an inflammatory response in which IL-6 is expressed in large amounts and the content of IL-6 in serum is increased. As shown in fig. 23, experimental data indicate that IL-6 levels in serum were significantly elevated in DSS mice compared to NC mice; the IL-6 content in serum was significantly reduced in mice of LSQ group compared to mice of DSS group. This shows that the triple fungus solid fermentation preparation can play a certain role in protecting inflammation of mice with colon inflammation.
4. Determination of the Effect of Triplex solid fermentation preparation on inflammatory factor TNF-alpha in mice with enteritis
ELISA method is used for measuring the influence of the triple fungus solid fermentation preparation on the mouse inflammatory factor TNF-alpha. Four weeks of animal experiment, collecting blood from eyeballs of mice after the experiment is finished, solidifying the blood at room temperature for 30min, and centrifuging at 3000r/min for 15min; the supernatant was aspirated and the content was determined using TNF- α ELISA kit.
During the onset of colitis, the increased TNF- α content is induced by the massive production of mononucleated and macrophages. As shown in fig. 23, experimental data indicate that TNF- α levels in the serum of DSS mice are significantly elevated compared to NC group; compared with the DSS mice, the serum of the LSQ mice has obviously reduced TNF-alpha content. This shows that the triple fungus solid fermentation preparation can play a certain role in recovering inflammation of mice with colon inflammation.
5. Determination of the Effect of Triplex solid fermentation preparation on inflammatory factor IL-10 in mice with enteritis
ELISA method is used for measuring the influence of the triple fungus solid fermentation preparation on the mouse inflammatory factor IL-10. Four weeks of animal experiment, collecting blood from eyeballs of mice after the experiment is finished, solidifying the blood at room temperature for 30min, and centrifuging at 3000r/min for 15min; the supernatant was aspirated and the content was determined using an IL-10ELISA kit.
IL-10 is one of the anti-inflammatory factors, has the functions of inhibiting the development of inflammation and immunosuppression, and is beneficial to restoring the colonic mucosa environment. Blood IL-10 levels increased when the symptoms of colitis were restored. As shown in fig. 23, the experimental data demonstrate that the serum IL-10 level was significantly increased in the DSS group mice compared to the NC group, and the serum IL-10 level was increased in the LSQ group mice compared to the DSS group mice. This shows that the triple fungus solid fermentation preparation can play a certain role in recovering inflammation of mice with colon inflammation.
6. Effect of solid state fermentation preparation on colon morphology of mice with colon inflammation
The colonic morphology changes of the colitis mice were observed using paraffin sections and H & E staining. Cutting the lower end colon tissue of the mouse to be not more than 1cm, fixing the lower end colon tissue by using 10% neutral formaldehyde solution, eluting by ethanol and transparent by dimethylbenzene, and then immersing the lower end colon tissue into paraffin for embedding; slicing and dewaxing again by using xylene; hematoxylin eosin is dyed, dehydrated, transparent and sealed, and observed by using a forward fluorescent microscope.
As shown in fig. 24, the colon goblet cells of the DSS group mice were deleted, and had more pronounced inflammatory cell infiltration, crypt disappeared, intestinal mucosa structure was destroyed, the colon goblet cells of the LSQ group mice were aligned, inflammatory symptoms were relieved, and gradually approached the normal colon morphology. The solid fermentation preparation of the triple bacteria can restore the intestinal tract of a colonitis mouse and has a certain protection effect on the colon.
In summary, the in vivo experiments in this example show that by inducing colitis by drinking DSS for one week, the colon length of the solid state fermentation formulation group is elongated and the level of IL-6 is reduced compared to the model group; and has significant differences; in addition, the colon section of the mice in the model group shows obvious inflammatory infiltration, goblet cells are lost, colon epithelial cells are destroyed, and the colon morphology of the mice is obviously recovered compared with the solid fermentation preparation group. This shows that the prepared triple fungus solid fermentation preparation plays a certain role in protecting mice with acute colitis induced by DSS. The method has important practical significance for preventing and treating the colonitis of animals.
The above embodiments are only illustrative of the preferred embodiments of the present invention and are not intended to limit the scope of the present invention, and various modifications and improvements made by those skilled in the art to the technical solutions of the present invention should fall within the protection scope defined by the claims of the present invention without departing from the design spirit of the present invention.
Claims (10)
1. A microbial combination for improving fermentation quality of medicated leaven, which is characterized BY comprising kluyveromyces marxianus (Kluyveromyces marxianus) JSA16, lactobacillus plantarum (Lactiplantibacillus plantarum) BY3 and bacillus subtilis (Bacillus subtilis) BK 3;
The Kluyveromyces marxianus JSA16 is preserved in the China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) at 2023 and a preservation address of North Star Xiyu No. 1, 3 in the Korean region of Beijing city, and a preservation number of CGMCC No.26422;
The lactobacillus plantarum BY3 is preserved in the China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) at the 12 th month of 2022, and has a preservation address of the No. 1 and No. 3 of the West road of North Star in the Korean area of Beijing, and a preservation number of CGMCC No.26262;
The bacillus subtilis BK3 is preserved in China general microbiological culture Collection center (China Committee for culture Collection of microorganisms) at the 12 th month of 2022, and has a preservation address of number 3 of West Song No. 1 of the Korean region North Star of Beijing city and a preservation number of CGMCC No.26260.
2. Use of the combination of microorganisms of claim 1 for the preparation of a triple bacterial solid state fermentation formulation.
3. The preparation method of the triple fungus solid state fermentation preparation is characterized by comprising the step of carrying out solid state fermentation on a raw material for preparing medicated leaven by utilizing the microorganism combination of claim 1 to prepare the triple fungus solid state fermentation preparation.
4. The preparation method according to claim 3, wherein the raw materials for preparing the medicated leaven comprise 50 parts by weight of wheat bran, 25 parts by weight of flour, 1 part by weight of bitter apricot seed, 1 part by weight of red bean, 5 parts by weight of polygonum hydropiper, 5 parts by weight of sweet wormwood and 5 parts by weight of xanthium sibiricum.
5. A method of preparation according to claim 3, characterized in that the method of preparation comprises the steps of:
(1) Pulverizing testa Tritici, flour and semen Armeniacae amarum, sterilizing and drying, adding water decoction of herba Polygoni Capitati, herba Artemisiae Annuae and herba Xanthii, and mixing to obtain solid fermentation preparation material;
(2) Inoculating the kluyveromyces marxianus JSA16, the lactobacillus plantarum BY3 and the bacillus subtilis BK3 into the solid fermentation preparation raw materials to prepare a yeast block, and performing solid fermentation to obtain the triple bacteria solid fermentation preparation.
6. The production method according to claim 5, wherein in the step (2), the inoculation mass fractions of the kluyveromyces marxianus JSA16, the lactobacillus plantarum BY3, and the bacillus subtilis BK3 with respect to the solid state fermentation preparation raw material are 3%, and 12%, respectively.
7. The method according to claim 5, wherein in the step (2), the solid state fermentation is performed at a temperature of 30℃for a period of 4d.
8. A triple fungus solid state fermentation preparation prepared according to the preparation method of any one of claims 3-7.
9. Use of the triple fungus solid state fermentation preparation of claim 8 in the preparation of feed, health food or medicament for relieving food retention and/or promoting digestion.
10. Use of the triple fungus solid state fermentation preparation of claim 8 in the preparation of a medicament for relieving colitis.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310944965.5A CN116970501B (en) | 2023-07-31 | 2023-07-31 | Triplex solid fermentation preparation and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310944965.5A CN116970501B (en) | 2023-07-31 | 2023-07-31 | Triplex solid fermentation preparation and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116970501A CN116970501A (en) | 2023-10-31 |
CN116970501B true CN116970501B (en) | 2024-05-14 |
Family
ID=88470867
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310944965.5A Active CN116970501B (en) | 2023-07-31 | 2023-07-31 | Triplex solid fermentation preparation and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116970501B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150106075A (en) * | 2014-03-11 | 2015-09-21 | 대구가톨릭대학교산학협력단 | Health food and pharmaceutical composition for preventing or improving intestinal disease comprising Bacillus subtilis strain or its culture broth as effective component |
CN107254424A (en) * | 2017-07-11 | 2017-10-17 | 福建贝迪药业有限公司 | A kind of livestock and poultry new liquid compound micro-ecological preparation and preparation method thereof |
CN107312730A (en) * | 2017-07-11 | 2017-11-03 | 福建贝迪药业有限公司 | A kind of compound Chinese herb probiotics and its Quick production method based on solid state fermentation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108485994B (en) * | 2018-03-07 | 2020-02-21 | 新疆天润生物科技股份有限公司 | Preparation method and application of compound milk beer freeze-dried fermentation microbial inoculum |
-
2023
- 2023-07-31 CN CN202310944965.5A patent/CN116970501B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20150106075A (en) * | 2014-03-11 | 2015-09-21 | 대구가톨릭대학교산학협력단 | Health food and pharmaceutical composition for preventing or improving intestinal disease comprising Bacillus subtilis strain or its culture broth as effective component |
CN107254424A (en) * | 2017-07-11 | 2017-10-17 | 福建贝迪药业有限公司 | A kind of livestock and poultry new liquid compound micro-ecological preparation and preparation method thereof |
CN107312730A (en) * | 2017-07-11 | 2017-11-03 | 福建贝迪药业有限公司 | A kind of compound Chinese herb probiotics and its Quick production method based on solid state fermentation |
Non-Patent Citations (3)
Title |
---|
六神曲固态协同发酵工艺优化及物质动态变化研究;马维维;戚岑聪;张艳聪;张洪梅;史晓飒;史新元;;中华中医药学刊;20170510(第05期);全文 * |
六神曲的发酵菌种分离及纯种发酵考察;邬吉野;李莹;王德馨;史新元;;中国实验方剂学杂志;20130820(第16期);全文 * |
神曲鲜干品组方对食积小鼠胃肠动力及肠道菌群调整的影响;王丽芳;高文远;徐鑫;张学栋;冯玛莉;白崇智;;中国实验方剂学杂志;20171231(第04期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN116970501A (en) | 2023-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104970252B (en) | A kind of fermentation liquid piglet feed and preparation method thereof | |
CN110835616B (en) | Active substance of lactobacillus paracasei GKS6, composition containing same and application of active substance in promoting longevity | |
CN107259578A (en) | A kind of probiotic composition and preparation method thereof | |
CN105942084A (en) | Method for producing probiotic functional food through buckwheat fermentation | |
CN108913639A (en) | A kind of Lactobacillus rhamnosus complexing agent and its preparation method and application | |
CN107488598B (en) | Burdock-based cordyceps militaris mycelium and preparation method thereof | |
CN106993807A (en) | A kind of preparation method of ginger ferment | |
CN105768106A (en) | Liver nutrition improving functional food | |
CN101036526A (en) | Buckwheat lactobacillus beverage and its preparing method | |
CN114908020A (en) | Lactobacillus plantarum for resisting helicobacter pylori infection and application of lactobacillus plantarum in edible herbal enzyme product | |
CN111109487A (en) | Fermented red rice beverage and preparation method thereof | |
KR101396842B1 (en) | Fermentation product of schisandra chinensis and antibacterial and immune enhancing composition comprising the same | |
US11085033B2 (en) | Glycosylated oxalate decarboxylase and preparation and application thereof | |
CN101613652A (en) | Tuckahoe health care white spirit and preparation method thereof | |
CN112515077A (en) | Functional lycium ruthenicum fermented drink and preparation method and application thereof | |
CN113615766A (en) | Preparation and application of composite plant extract and probiotic biological fermentation feed | |
CN113755377A (en) | Paramycosis bacillus preparation for degrading uric acid and preparation method and application thereof | |
CN112931866A (en) | Edible amino acid enzyme and preparation method thereof | |
CN116970501B (en) | Triplex solid fermentation preparation and preparation method and application thereof | |
CN101912423B (en) | Method for manufacturing Monascus products containing probiotics | |
CN109700014A (en) | A kind of preparation method of rice bran probiotics ferment | |
CN113774000B (en) | Bifidobacterium animalis fermentation filtrate, preparation method and application thereof | |
TWI711458B (en) | Plant ferment, preparation method thereof and use thereof for stomach health care | |
CN112322444A (en) | Preparation method of sweet potato vinegar beverage | |
CN117099850B (en) | Fermented plant-based yoghurt and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |